1. Home
  2. STIM vs IMUX Comparison

STIM vs IMUX Comparison

Compare STIM & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuronetics Inc.

STIM

Neuronetics Inc.

HOLD

Current Price

$1.19

Market Cap

140.6M

Sector

Health Care

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$11.03

Market Cap

152.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STIM
IMUX
Founded
2003
2016
Country
United States
United States
Employees
N/A
66
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
140.6M
152.6M
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
STIM
IMUX
Price
$1.19
$11.03
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$3.00
$36.00
AVG Volume (30 Days)
2.6M
845.2K
Earning Date
05-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
57.25
38.00
EPS
N/A
N/A
Revenue
$52,776,000.00
N/A
Revenue This Year
$11.10
N/A
Revenue Next Year
$11.92
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$0.51
52 Week High
$4.84
$13.30

Technical Indicators

Market Signals
Indicator
STIM
IMUX
Relative Strength Index (RSI) 38.06 66.65
Support Level $0.80 $0.75
Resistance Level $1.55 $13.30
Average True Range (ATR) 0.20 0.95
MACD -0.08 -0.25
Stochastic Oscillator 4.78 43.03

Price Performance

Historical Comparison
STIM
IMUX

About STIM Neuronetics Inc.

Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: